Related Experiment Video
Updated: May 29, 2026
13:08
Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
Published on: September 9, 2012
Blood coagulation factor XII--a neglected player in stroke pathophysiology
Mirko Pham1, Guido Stoll, Bernhard Nieswandt
1Department of Neuroradiology, Heidelberg University Hospital, INF 400, 69120 Heidelberg, Germany. mirko.pham@med.uni-heidelberg.de
Journal of Molecular Medicine (Berlin, Germany)
|September 13, 2011
Summary
Factor XII (FXII) plays a key role in pathological clot formation during ischemic stroke. Inhibiting FXII offers a promising therapeutic strategy for stroke treatment with reduced bleeding risks.
Area of Science:
- Neurology
- Hematology
- Vascular Biology
Background:
- Ischemic stroke, often caused by arterial thrombosis, lacks effective antithrombotic treatments due to limited efficacy and bleeding risks.
- The precise mechanisms of microvascular thrombus formation in cerebral ischemia remain unclear.
- Factor XII (FXII) initiates the intrinsic coagulation pathway, but its physiological role in hemostasis has been debated due to FXII deficiency not causing bleeding in humans.
Purpose of the Study:
- To review the pathophysiological role of FXII in experimental cerebral ischemia.
- To highlight novel therapeutic strategies targeting FXII inhibition for ischemic stroke.
Main Methods:
- Review of existing literature on FXII's role in coagulation and thromboembolism.
- Analysis of studies in transgenic mice demonstrating FXII's role in pathological thrombus formation.
- Examination of experimental models of ischemic stroke.
Main Results:
- FXII deficiency in mice prevents pathological thrombus formation without impairing normal hemostasis.
- Recent findings challenge the long-held view of FXII's non-essential role in hemostasis.
- FXII is implicated in the development of pathological thrombus in cerebral ischemia models.
Conclusions:
- FXII is a critical factor in pathological thrombus formation during ischemic stroke.
- Targeting FXII with inhibitors presents a novel and potentially safer therapeutic approach for stroke.
- Further research into FXII inhibition could lead to improved stroke treatments.
More Related Videos
Related Concept Videos
01:20Extrinsic and Intrinsic Pathways of Hemostasis
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:29Hemorrhagic Stroke ll: Pathophysiology
A hemorrhagic stroke develops when a cerebral blood vessel ruptures, allowing blood to escape into the surrounding brain tissue, as in intracerebral hemorrhage (ICH), or into the subarachnoid space, as in subarachnoid hemorrhage (SAH). Because the skull is a rigid compartment, the sudden presence of extravascular blood rapidly increases intracranial pressure and compresses adjacent neural structures, leading to immediate tissue injury and impaired cerebral perfusion.Mass Effect and Primary...
01:24Disorders of Hemostasis
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
01:16Clot Retraction and Fibrinolysis
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
01:09Coagulation
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...